OBJECTIVES: The concentration in plasma of the brain-specific cholesterol metabolite cerebrosterol has been proposed as a biomarker of neurodegeneration in multiple sclerosis (MS) and other neurological diseases. It is unknown, however, which pathophysiological process in MS best accounts for variations in plasma cerebrosterol. PATIENTS AND METHODS: In this study, we related plasma cerebrosterol concentrations in 46 MS patients - 27 with a relapsing-remitting (RR) disease course and 19 with a primary progressive (PP) course - to three conventional magnetic resonance imaging measures: on T(1)-weighted brain scans, volume of gadolinium-enhanced lesions (a marker of active inflammation) and hypointense lesions (a marker of edema or axonal loss) and on T(2)-weighted scans, volume of hyperintense lesions (a marker of disease extent). RESULTS: By multiple-regression analysis, we uncovered negative correlations between the cerebrosterol-cholesterol ratio in plasma and both age at sampling (beta=-0.35 and p=0.079 in RRMS; beta=-0.76 and p=0.006 in PPMS) and volume of T(2)-weighted lesions (beta=-0.52 and p=0.078 in RRMS; beta=-0.50 and p=0.247 in PPMS). CONCLUSION: We hypothesize that decreases in plasma cerebrosterol may reflect the total spatiotemporal burden of MS-the cumulative effects of its dissemination in space and its duration in time.
OBJECTIVES: The concentration in plasma of the brain-specific cholesterol metabolite cerebrosterol has been proposed as a biomarker of neurodegeneration in multiple sclerosis (MS) and other neurological diseases. It is unknown, however, which pathophysiological process in MS best accounts for variations in plasma cerebrosterol. PATIENTS AND METHODS: In this study, we related plasma cerebrosterol concentrations in 46 MS patients - 27 with a relapsing-remitting (RR) disease course and 19 with a primary progressive (PP) course - to three conventional magnetic resonance imaging measures: on T(1)-weighted brain scans, volume of gadolinium-enhanced lesions (a marker of active inflammation) and hypointense lesions (a marker of edema or axonal loss) and on T(2)-weighted scans, volume of hyperintense lesions (a marker of disease extent). RESULTS: By multiple-regression analysis, we uncovered negative correlations between the cerebrosterol-cholesterol ratio in plasma and both age at sampling (beta=-0.35 and p=0.079 in RRMS; beta=-0.76 and p=0.006 in PPMS) and volume of T(2)-weighted lesions (beta=-0.52 and p=0.078 in RRMS; beta=-0.50 and p=0.247 in PPMS). CONCLUSION: We hypothesize that decreases in plasma cerebrosterol may reflect the total spatiotemporal burden of MS-the cumulative effects of its dissemination in space and its duration in time.
Authors: Timothy M Hughes; Lewis H Kuller; Oscar L Lopez; James T Becker; Rhobert W Evans; Kim Sutton-Tyrrell; Caterina Rosano Journal: J Alzheimers Dis Date: 2012 Impact factor: 4.472
Authors: Alana C Costa; Helena P G Joaquim; Valéria S Nunes; Daniel S Kerr; Guilherme S Ferreira; Orestes V Forlenza; Wagner F Gattaz; Leda Leme Talib Journal: Eur Arch Psychiatry Clin Neurosci Date: 2017-08-31 Impact factor: 5.270
Authors: Victoria J Williams; Elizabeth C Leritz; Juli Shepel; Regina E McGlinchey; William P Milberg; James L Rudolph; Lewis A Lipsitz; David H Salat Journal: Hum Brain Mapp Date: 2012-03-22 Impact factor: 5.038
Authors: Rohini Sidhu; Hui Jiang; Nicole Y Farhat; Nuria Carrillo-Carrasco; Myra Woolery; Elizabeth Ottinger; Forbes D Porter; Jean E Schaffer; Daniel S Ory; Xuntian Jiang Journal: J Lipid Res Date: 2015-04-12 Impact factor: 5.922